[ad_1]
PETALING JAYA: Researchers at the New York-based Mount Sinai Covid Computer Center have found that anticoagulants can improve the survival chances of patients with Covid-19.
They reported in the May 6 issue of the Journal of the American College of Cardiology that treating hospitalized patients with Covid-19 anticoagulants, that is, anticoagulants that decrease clotting, may improve their chances of survival.
The Mount Sinai researchers’ work described a potentially important therapeutic pathway for patients with Covid-19.
The study found that hospitalized Covid-19 patients treated with anticoagulants had improved outcomes both inside and outside the intensive care unit.
However, the researchers cautioned that each case should be evaluated individually in light of the potential risks of bleeding.
The study was published after findings at the Icahn School of Medicine at Mount Sinai, which showed that large numbers of patients hospitalized with Covid-19 had developed high levels of life-threatening blood clots, leading to life-threatening thromboembolic events.
A team of researchers evaluated the records of 2,773 confirmed Covid-19 positive patients admitted to five Mount Sinai Health System hospitals in New York City (Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Queens and Mount Sinai Brooklyn) between March 14 and April 11, 2020.
They specifically looked at the survival rates of patients who received anticoagulants versus those who did not receive anticoagulants.
They also considered certain risk factors before evaluating the effectiveness of anticoagulation, including age, ethnicity, pre-existing conditions, and those already on anticoagulants.
Another article published in the Journal of Thrombosis and Haemostasis on April 22 also suggested early therapeutic anticoagulation for severe cases.
The findings are consistent with autopsies performed in Italy showing signs of massive thrombosis.
Italian expert in echocardiography and interventional cardiology, Dr. Giampaolo Palma, said that thrombosis was possibly the leading cause of death for Covid-19.
“It is venous microthrombosis, not pneumonia, that determines mortality,” said Dr. Palma.
He is one of many Italian doctors who use blood-thinning medications in treatment with Covid-19 and actively exchange information about it through a national network.
[ad_2]
